The Predictive Value of P53, P53R2, and P21 for the Effect of Chemoradiation Therapy on Oesophageal Squamous Cell Carcinoma

Overview

Journal Br J Cancer

Specialty Oncology

Date 2005 Jan 19

PMID 15655547

Citations 16

Authors

H Okumura

S Natsugoe

M Matsumoto

Y Mataki

H Takatori

S Ishigami

S Takao

T Aikou

Affiliations

Soon will be listed here.

Abstract

The p53 family regulates cell-cycle arrest, triggers apoptosis or is involved in repair of DNA damage. In the present study, we analysed the expression of some p53 family proteins and their responses to chemoradiation therapy (CRT) in cases of oesophageal squamous cell carcinoma (ESCC). We immunohistochemically investigated the relationship between p53, p53R2, and p21 expression in biopsy specimens of untreated primary tumours and their clinical and histological responses to CRT in 62 patients with ESCC. Chemoradiation therapy consisted of 5-fluorouracil plus cisplatin and 40 Gy of radiation. The rates of clinical and histological responses (complete or partial) to CRT were 71.0% (clinical) and 52.8% (histological). The rate of positive expression was 43.5% for p53, 37.1% for p53R2, and 54.8% for p21 expression. Statistically significant correlations were found between p53 or p53R2 expression and favourable response to CRT (P=0.0001 or 0.041 clinical, P=0.016 or 0.0018 histological, respectively). Furthermore, in p53-negative tumours, CRT was more effective in tumours with p53R2 negative expression than those with p53R2 positive expression (P=0.0014). We demonstrated that the negative expression of p53 and p53R2 expression was closely related to the effect of CRT and should predict the CRT outcome in patients with ESCC.

Citing Articles

RRM2B Is Frequently Amplified Across Multiple Tumor Types: Implications for DNA Repair, Cellular Survival, and Cancer Therapy.

Iqbal W, Demidova E, Serrao S, ValizadehAslani T, Rosen G, Arora S Front Genet. 2021; 12:628758.

PMID: 33868369 PMC: 8045241. DOI: 10.3389/fgene.2021.628758.

Role of precision imaging in esophageal cancer.

Elsherif S, Andreou S, Virarkar M, Soule E, Gopireddy D, Bhosale P J Thorac Dis. 2020; 12(9):5159-5176.

PMID: 33145093 PMC: 7578477. DOI: 10.21037/jtd.2019.08.15.

Enhancing radiosensitivity of TE1, TE8, and TE 11 esophageal squamous carcinoma cell lines by Hdm2-siRNA targeted gene therapy in vitro.

Islamian J, Mohammadi M, Baradaran B, Farajollahi A, Aghamiri S, Jafarabadi M Bioimpacts. 2016; 6(2):93-8.

PMID: 27525226 PMC: 4981254. DOI: 10.15171/bi.2016.13.

Correlation of Aurora-A expression with the effect of chemoradiation therapy on esophageal squamous cell carcinoma.

Tamotsu K, Okumura H, Uchikado Y, Kita Y, Sasaki K, Omoto I BMC Cancer. 2015; 15:323.

PMID: 25924824 PMC: 4423148. DOI: 10.1186/s12885-015-1329-3.

Murine double minute 2 predicts response of advanced esophageal squamous cell carcinoma to definitive chemoradiotherapy.

Okamoto H, Fujishima F, Kamei T, Nakamura Y, Ozawa Y, Miyata G BMC Cancer. 2015; 15:208.

PMID: 25880782 PMC: 4392620. DOI: 10.1186/s12885-015-1222-0.

References

Kishi K, Doki Y, Miyata H, Yano M, Yasuda T, Monden M . Prediction of the response to chemoradiation and prognosis in oesophageal squamous cancer. Br J Surg. 2002; 89(5):597-603. DOI: 10.1046/j.1365-2168.2002.02057.x. View

Yamaguchi T, Matsuda K, Sagiya Y, Iwadate M, Fujino M, Nakamura Y . p53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle checkpoint. Cancer Res. 2001; 61(22):8256-62. View

Naunheim K, Petruska P, Roy T, ANDRUS C, Johnson F, Schlueter J . Preoperative chemotherapy and radiotherapy for esophageal carcinoma. J Thorac Cardiovasc Surg. 1992; 103(5):887-93; discussion 893-5. View

Nakashima S, Natsugoe S, Matsumoto M, Kijima F, Takebayashi Y, Okumura H . Expression of p53 and p21 is useful for the prediction of preoperative chemotherapeutic effects in esophageal carcinoma. Anticancer Res. 2000; 20(3B):1933-7. View

Kastan M, Onyekwere O, Sidransky D, Vogelstein B, Craig R . Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991; 51(23 Pt 1):6304-11. View

Lowe S, Bodis S, McClatchey A, Remington L, Ruley H, Fisher D . p53 status and the efficacy of cancer therapy in vivo. Science. 1994; 266(5186):807-10. DOI: 10.1126/science.7973635. View

Nakano S, Baba M, Natsugoe S, Kusano C, Shimada M, Fukumoto T . The role of neoadjuvant radiochemotherapy using low-dose fraction cisplatin and 5-fluorouracil in patients with carcinoma of the esophagus. Jpn J Thorac Cardiovasc Surg. 2001; 49(1):11-6. DOI: 10.1007/BF02913117. View

Natsugoe S, Nakashima S, Matsumoto M, Xiangming C, Okumura H, Kijima F . Expression of p21WAF1/Cip1 in the p53-dependent pathway is related to prognosis in patients with advanced esophageal carcinoma. Clin Cancer Res. 1999; 5(9):2445-9. View

Baba M, Aikou T, Yoshinaka H, Natsugoe S, Fukumoto T, Shimazu H . Long-term results of subtotal esophagectomy with three-field lymphadenectomy for carcinoma of the thoracic esophagus. Ann Surg. 1994; 219(3):310-6. PMC: 1243140. DOI: 10.1097/00000658-199403000-00012. View

10.

Caelles C, Helmberg A, Karin M . p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature. 1994; 370(6486):220-3. DOI: 10.1038/370220a0. View

11.

John M, Flam M, Mowry P, Podolsky W, Xavier A, Wittlinger P . Radiotherapy alone and chemoradiation for nonmetastatic esophageal carcinoma. A critical review of chemoradiation. Cancer. 1989; 63(12):2397-403. DOI: 10.1002/1097-0142(19890615)63:12<2397::aid-cncr2820631204>3.0.co;2-s. View

12.

Thompson C . Apoptosis in the pathogenesis and treatment of disease. Science. 1995; 267(5203):1456-62. DOI: 10.1126/science.7878464. View

13.

Sarbia M, Stahl M, Fink U, Willers R, Seeber S, Gabbert H . Expression of apoptosis-regulating proteins and outcome of esophageal cancer patients treated by combined therapy modalities. Clin Cancer Res. 1998; 4(12):2991-7. View

14.

Hollstein M, Sidransky D, Vogelstein B, Harris C . p53 mutations in human cancers. Science. 1991; 253(5015):49-53. DOI: 10.1126/science.1905840. View

15.

Wagata T, Shibagaki I, Imamura M, Shimada Y, Toguchida J, Yandell D . Loss of 17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinomas. Cancer Res. 1993; 53(4):846-50. View

16.

Xiong Y, Hannon G, Zhang H, Casso D, Kobayashi R, Beach D . p21 is a universal inhibitor of cyclin kinases. Nature. 1993; 366(6456):701-4. DOI: 10.1038/366701a0. View

17.

Japanese Society for Esophageal Diseases . Guide lines for the clinical and pathologic studies on carcinoma of the esophagus. Jpn J Surg. 1976; 6(2):69-78. DOI: 10.1007/BF02468889. View

18.

Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K . A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature. 2000; 404(6773):42-9. DOI: 10.1038/35003506. View

19.

Vogelstein B, Kinzler K . p53 function and dysfunction. Cell. 1992; 70(4):523-6. DOI: 10.1016/0092-8674(92)90421-8. View

20.

Byun D, Chae K, Ryu B, Lee M, Chi S . Expression and mutation analyses of P53R2, a newly identified p53 target for DNA repair in human gastric carcinoma. Int J Cancer. 2002; 98(5):718-23. DOI: 10.1002/ijc.10253. View